Immunocore1.png
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
May 06, 2020 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...
Immunocore1.png
Immunocore Secures $130 Million Series B Financing
March 02, 2020 07:00 ET | Immunocore Limited
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
logo.jpg
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
November 19, 2018 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...
logo.jpg
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
November 19, 2018 02:00 ET | Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...
logo.jpg
Immunocore strengthens IP position in the field of TCR-based therapeutics
September 05, 2018 07:00 ET | Immunocore Limited
Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
logo.jpg
Immunocore strengthens IP position in the field of TCR-based therapeutics
September 05, 2018 02:00 ET | Immunocore Limited
PRESS RELEASE Immunocore strengthens IP position in the field of TCR-based therapeutics Notice of Allowance received from US patent and trademark office relating to ImmTAC® platform (Oxford, UK and...
logo.jpg
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
August 20, 2018 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
August 20, 2018 02:00 ET | Immunocore Limited
PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours Study of IMCnyeso in NSCLC, Bladder Cancer, Melanoma and Synovial Sarcoma is the first in GSK...